Profile data is unavailable for this security.
About the company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
- Revenue in USD (TTM)1.97m
- Net income in USD-235.46m
- Incorporated2008
- Employees290.00
- LocationCrinetics Pharmaceuticals Inc10222 Barnes Canyon Rd Bldg 2SAN DIEGO 92121-2711United StatesUSA
- Phone+1 (858) 450-6464
- Fax+1 (302) 636-5454
- Websitehttps://www.crinetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.87bn | 251.00 | -- | 3.24 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.90bn | 517.00 | -- | 22.21 | -- | 6.85 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.07bn | 305.00 | -- | 5.41 | -- | 116.12 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.10bn | 239.00 | -- | 9.53 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.40m | 3.11bn | 143.00 | -- | 5.81 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.14bn | 352.00 | 28.22 | 5.73 | 26.39 | 6.00 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Guardant Health Inc | 603.73m | -460.90m | 3.32bn | 1.78k | -- | 48.33 | -- | 5.49 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.34bn | 1.28k | -- | 23.78 | -- | 7.54 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.49bn | 545.00 | -- | 24.20 | -- | 13.89 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Crinetics Pharmaceuticals Inc | 1.97m | -235.46m | 3.50bn | 290.00 | -- | 3.99 | -- | 1,774.14 | -3.77 | -3.77 | 0.0315 | 11.14 | 0.0031 | -- | 0.3653 | 6,806.90 | -35.57 | -42.53 | -37.86 | -45.36 | -- | -- | -11,641.13 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Merus NV | 38.34m | -149.65m | 3.59bn | 172.00 | -- | 8.94 | -- | 93.56 | -2.72 | -2.72 | 0.7031 | 5.95 | 0.0917 | -- | 1.21 | 222,889.50 | -35.78 | -29.35 | -43.82 | -35.36 | -- | -- | -390.36 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| Immunovant Inc | 0.00 | -259.34m | 3.71bn | 207.00 | -- | 5.98 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.85bn | 271.00 | 27.63 | 2.34 | 23.77 | 3.04 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 3.96bn | 2.10k | 6.68 | 3.16 | 5.96 | 2.29 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Data as of May 31 2024. Currency figures normalised to Crinetics Pharmaceuticals Inc's reporting currency: US Dollar USD
50.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Driehaus Capital Management LLCas of 31 Mar 2024 | 5.23m | 6.71% |
| Point72 Asset Management LPas of 31 Mar 2024 | 4.95m | 6.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.86m | 6.24% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 4.16m | 5.33% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.91m | 5.02% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.74m | 4.80% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.46m | 4.44% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.26m | 4.18% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 3.12m | 4.01% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 2.97m | 3.81% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
